drugset
drugset / Trial / NCT04349969

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

NCT04349969 ↗

Phase 1 Completed 38 enrolled Akeso Biopharma, Inc.
NaSequentialOpen-labelTreatment

Summary

This was a first-in-human, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 as monotherapy or in combination with AK104 in subjects with advanced or metastatic solid tumors.

Timeline

Start
2020-04-23
Primary completion
2022-11-08
Completion
2022-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject AK117 Monoclonal antibody — Intravenous
Subject Cadonilimab Monoclonal antibody — Intravenous

Indications

cancer